Trials / Completed
CompletedNCT04784689
Host Immune Response to Novel RNA COVID-19 Vaccination
Host Immune Response to Novel RNA COVID-19 Vaccination in Patients With Cancer (CTMS# 21-0012)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 50 (actual)
- Sponsor
- The University of Texas Health Science Center at San Antonio · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
To determine the antibody response level in patients with cancer to the COVID-19 vaccination.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | COVID-19 Vaccine | COVID-19 Vaccine |
Timeline
- Start date
- 2021-02-24
- Primary completion
- 2022-05-18
- Completion
- 2022-05-18
- First posted
- 2021-03-05
- Last updated
- 2023-05-25
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT04784689. Inclusion in this directory is not an endorsement.